Showing results (101-110 of 253) with videos related to

Sort By:
Pageof 26
Seminars in Nephrology|March 16, 2004
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans-Henrik Parving, Steen Andersen, Peter Jacobsen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|July 9, 2008
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) studyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Annals of Internal Medicine|May 20, 2009
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trialsRudy Bilous, Nish Chaturvedi, Anne Katrin Sjølie, et al.
Journal of Hypertension|November 7, 2007
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up studyAnne Sofie Astrup, Flemming S Nielsen, Peter Rossing, et al.
Clinical Chemistry|October 16, 2010
Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitusSøren S Lund, Martin Petersen, Merete Frandsen, et al.
Diabetes, Obesity & Metabolism|April 1, 2018
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweightJeroen V Koomen, Jasper Stevens, Nael M Mostafa, et al.
BMJ (Clinical Research Ed.)|April 21, 2004
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort studyPeter Hovind, Lise Tarnow, Peter Rossing, et al.
European Journal of Endocrinology|January 16, 2007
An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetesPeter Hovind, Steven Lamberts, Wim Hop, et al.
Pageof 26